<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520987</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-126</org_study_id>
    <nct_id>NCT01520987</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled, multiple ascending dose, parallel-group,
      pharmacokinetic (PK) and pharmacodynamic (PD) study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax - maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</measure>
    <time_frame>Day 10</time_frame>
    <description>Cmax - maximum observed plasma concentration following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC0-t - area under the concentration-time curve (AUC) from time zero to last time point with concentrations above the lower limit of quantitation of BIA 9-1067 following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 10)</measure>
    <time_frame>Day 10</time_frame>
    <description>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC0-∞ - area under the concentration of BIA 9-1067-time curve (AUC) from time zero to infinity following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 10)</measure>
    <time_frame>Day 10</time_frame>
    <description>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax of BIA 9-1067 - time taken to reach maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</measure>
    <time_frame>Day 10</time_frame>
    <description>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Caucasian 5 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian 25 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian 50 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, PLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese 5 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese 25 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese 50 mg OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, opicapone, BIA 9-1067</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, PLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
    <arm_group_label>Caucasian 5 mg OPC</arm_group_label>
    <arm_group_label>Caucasian 25 mg OPC</arm_group_label>
    <arm_group_label>Caucasian 50 mg OPC</arm_group_label>
    <arm_group_label>Japanese 5 mg OPC</arm_group_label>
    <arm_group_label>Japanese 25 mg OPC</arm_group_label>
    <arm_group_label>Japanese 50 mg OPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once-daily</description>
    <arm_group_label>Caucasian Placebo</arm_group_label>
    <arm_group_label>Japanese Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or nonlactating and nonpregnant women;

          -  Caucasian or Japanese subjects. Caucasian subjects are subjects of European descent;
             Japanese subjects must be first or second generation. Generations will be defined as
             follows:

               1. First generation Japanese are subjects who may be living outside Japan but were
                  born in Japan to parents of Japanese descent.

               2. Second generation Japanese are subjects who were born outside of Japan to first
                  generation Japanese parents.

          -  Aged 18 to 65 years;

          -  Body weight ≥50 kg;

          -  Within BMI range 18.5 to 30 kg/m2, inclusive;

          -  Healthy, as determined by the Investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs, and 12-lead ECG.
             Creatinine and ALT levels must be strictly within the normal range for eligibility at
             Check-in;

          -  Women of nonchildbearing potential must be surgically sterile (hysterectomy,
             oophorectomy, or tubal ligation) or postmenopausal for ≥1 year;

          -  Women of childbearing potential must be using an effective nonhormonal method of
             contraception (intrauterine device or intrauterine system; condom or occlusive cap
             [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or
             suppository; true abstinence; or vasectomized male partner, provided that he is the
             sole partner of that subject) for a period of at least 1 month before and after dose
             administration. Women of childbearing potential must have a negative pregnancy test
             result within 48 hours before the start of the first investigational medicinal product
             (IMP) administration. Hormonal contraceptives will not be allowed because the effect
             of BIA 9 1067 on the metabolism of hormonal contraceptives and vice versa is not yet
             known;

          -  Nonsmokers, defined as having smoked ≤10 cigarettes per week for the 3 months prior to
             dosing, abstained from smoking for 7 days prior to Check-in, and having a negative
             cotinine level ≤500 ng/mL at Check-in;

          -  Have a high probability for compliance with and completion of the study, in the
             opinion of the Investigator;

          -  Able to comprehend and willing to sign an ICF.

        Exclusion Criteria:

          -  Presence or history of any disorder that may prevent the successful completion of the
             study;

          -  History of multiple and/or severe allergies to drugs or foods or a history of
             anaphylactic reactions;

          -  Known or suspected allergy or other adverse drug reactions to the trial product or
             related products (eg, tolcapone or entacapone);

          -  History of alcoholism or excessive daily alcohol consumption within the past year.
             Excessive alcohol consumption is regarded as an average weekly intake of more than 14
             units for women and 21 units for men (1 unit of alcohol = 8 to 10 g and is
             approximately equivalent to 1 glass of wine or 250 mL of beer or a standard measure of
             spirits);

          -  Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease,
             as judged by the Investigator or Sponsor's Medical Monitor;

          -  Any clinically important deviation from normal limits in physical examination, vital
             signs, or 12-lead ECGs, as judged by the Investigator or Sponsor's Medical Monitor;

          -  Acute disease state (eg, nausea, vomiting, fever, diarrhea) within 7 days of Study Day
             1;

          -  Positive serologic findings for HIV antibodies, hepatitis B surface antigen (HBsAg),
             and/or hepatitis C virus antibodies (anti-HCV);

          -  Positive screen for drugs of abuse and alcohol;

          -  Recent history or presence of any disorder that may interfere with the absorption,
             distribution, metabolism, or excretion of BIA 9 1067;

          -  Positive pregnancy test result for WOCBP only;

          -  Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or cola),
             grapefruit, grapefruit-containing products, or alcoholic beverages from 48 hours
             before Study Day 1 until Discharge (Day 16);

          -  Involvement in other investigational studies of any type within 30 days of BIA 9-1067
             administration;

          -  Donation of blood within 90 days of Study Day 1;

          -  Use of any prescription drug within 30 days of IMP administration unless deemed
             acceptable by the Principal Investigator (PI) and Medical Monitor;

          -  Use of any over-the-counter drugs including herbal supplements (except for the
             occasional use of acetaminophen and vitamins ≤100% recommended daily allowance) within
             14 days of Study Day 1 unless deemed acceptable by the PI and Medical Monitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haejung Marr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>May 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2016</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Caucasian 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P2">
          <title>Caucasian 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P3">
          <title>Caucasian 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P4">
          <title>Caucasian Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
        <group group_id="P5">
          <title>Japanese 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P6">
          <title>Japanese 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P7">
          <title>Japanese 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="P8">
          <title>Japanese Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dosed</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caucasian 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B2">
          <title>Caucasian 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B3">
          <title>Caucasian 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B4">
          <title>Caucasian Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
        <group group_id="B5">
          <title>Japanese 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B6">
          <title>Japanese 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B7">
          <title>Japanese 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="B8">
          <title>Japanese Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</title>
        <description>Cmax - maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</title>
          <description>Cmax - maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" spread="64.5"/>
                    <measurement group_id="O2" value="794" spread="392"/>
                    <measurement group_id="O3" value="1540" spread="493"/>
                    <measurement group_id="O4" value="176" spread="93.6"/>
                    <measurement group_id="O5" value="797" spread="323"/>
                    <measurement group_id="O6" value="1736" spread="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</title>
        <description>Cmax - maximum observed plasma concentration following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</title>
          <description>Cmax - maximum observed plasma concentration following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" spread="110"/>
                    <measurement group_id="O2" value="774" spread="361"/>
                    <measurement group_id="O3" value="1550" spread="655"/>
                    <measurement group_id="O4" value="276" spread="130"/>
                    <measurement group_id="O5" value="959" spread="273"/>
                    <measurement group_id="O6" value="1785" spread="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 1)</title>
        <description>AUC0-t - area under the concentration-time curve (AUC) from time zero to last time point with concentrations above the lower limit of quantitation of BIA 9-1067 following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 1)</title>
          <description>AUC0-t - area under the concentration-time curve (AUC) from time zero to last time point with concentrations above the lower limit of quantitation of BIA 9-1067 following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose.</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="113"/>
                    <measurement group_id="O2" value="2013" spread="800"/>
                    <measurement group_id="O3" value="3727" spread="1726"/>
                    <measurement group_id="O4" value="319" spread="154"/>
                    <measurement group_id="O5" value="1886" spread="692"/>
                    <measurement group_id="O6" value="4438" spread="1151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 10)</title>
        <description>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 (Day 10)</title>
          <description>AUC0-t - Area Under the Concentration-time Curve (AUC) From Time Zero to Last Time Point With Concentrations Above the Lower Limit of Quantitation of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349" spread="169"/>
                    <measurement group_id="O2" value="2024" spread="820"/>
                    <measurement group_id="O3" value="3999" spread="1770"/>
                    <measurement group_id="O4" value="441" spread="139"/>
                    <measurement group_id="O5" value="2222" spread="407"/>
                    <measurement group_id="O6" value="4464" spread="932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 1)</title>
        <description>AUC0-∞ - area under the concentration of BIA 9-1067-time curve (AUC) from time zero to infinity following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 1)</title>
          <description>AUC0-∞ - area under the concentration of BIA 9-1067-time curve (AUC) from time zero to infinity following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" spread="48.6"/>
                    <measurement group_id="O2" value="2039" spread="798"/>
                    <measurement group_id="O3" value="3756" spread="1734"/>
                    <measurement group_id="O4" value="357" spread="163"/>
                    <measurement group_id="O5" value="1976" spread="673"/>
                    <measurement group_id="O6" value="4470" spread="1147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 10)</title>
        <description>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity (Day 10)</title>
          <description>AUC0-∞ - Area Under the Concentration of BIA 9-1067-time Curve (AUC) From Time Zero to Infinity following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409" spread="147"/>
                    <measurement group_id="O2" value="2056" spread="817"/>
                    <measurement group_id="O3" value="4028" spread="1786"/>
                    <measurement group_id="O4" value="465" spread="145"/>
                    <measurement group_id="O5" value="2240" spread="406"/>
                    <measurement group_id="O6" value="4510" spread="938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</title>
        <description>Tmax of BIA 9-1067 - time taken to reach maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1)</title>
          <description>Tmax of BIA 9-1067 - time taken to reach maximum observed plasma concentration following single (Day 1) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: on Day 1 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.75" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="2.0" lower_limit="1.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.75" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</title>
        <description>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caucasian 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O2">
            <title>Caucasian 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O3">
            <title>Caucasian 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O4">
            <title>Japanese 5 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O5">
            <title>Japanese 25 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
          <group group_id="O6">
            <title>Japanese 50 mg OPC</title>
            <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 (Day 10)</title>
          <description>Tmax of BIA 9-1067 - Time Taken to Reach Maximum Observed Plasma Concentration of BIA 9-1067 following Last (Day 10) oral administrations of 5, 25 and 50 mg OPC in healthy Japanese and matched healthy Caucasian subjects.
Blood samples collected for PK analysis at the following timepoints: Day 10 at pre-dose (within 1 hour before dose administration) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120, and 144 hours post-dose</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="5.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.50" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.75" upper_limit="5.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caucasian 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E2">
          <title>Caucasian 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E3">
          <title>Caucasian 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E4">
          <title>Caucasian Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
        <group group_id="E5">
          <title>Japanese 5 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E6">
          <title>Japanese 25 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E7">
          <title>Japanese 50 mg OPC</title>
          <description>OPC, opicapone, BIA 9-1067
BIA 9-1067: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).</description>
        </group>
        <group group_id="E8">
          <title>Japanese Placebo</title>
          <description>Placebo, PLC
Placebo: once-daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Laceratioin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stifness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

